4.7 Review

New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies

Journal

JOURNAL OF INVESTIGATIVE DERMATOLOGY
Volume 141, Issue 10, Pages 2328-2337

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jid.2021.02.743

Keywords

-

Categories

Funding

  1. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis
  2. National Institutes of Health Intramural Research Program [Z01 HL-06193]
  3. National Institutes of Health [U01-AI119125]
  4. National Psoriasis Foundation

Ask authors/readers for more resources

Psoriasis and psoriatic arthritis are not just diseases of the skin and joints, but rather immune dysfunction disorders caused by a combination of innate and environmental factors. Understanding the pathogenesis and systemic effects of psoriatic inflammation has led to the development of new and more effective treatments.
Although psoriasis and psoriatic arthritis (PsA) have been classically considered to be diseases of the skin and joints, respectively, emerging evidence suggests that a combination of innate and environmental factors creates widespread immune dysfunction, affecting multiple organ systems. A greater understanding of the pathogenesis of psoriasis and the systemic effects of psoriatic inflammation has allowed for the development of new, more effective treatments. The second portion of this two-part review series examines the comorbidities associated with psoriasis and PsA as well as the most recent advances in targeted systemic therapies for these conditions.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available